Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 09, 2026
TickeronGET DAILY SIGNALS
Why Is Humana (HUM) Stock Up +14.47% Today?

Why Is Humana (HUM) Stock Up +14.47% Today?

Key Takeaways

  • Humana (HUM) shares surged +14.47%, climbing from a prior close of $387.12 to roughly $443.14.
  • The primary catalyst was a Medicare Advantage Star Ratings upgrade from the Centers for Medicare & Medicaid Services (CMS).
  • Humana's largest contract regained a four-star rating, restoring eligibility for federal quality bonus payments.
  • Analyst actions amplified the rally, including a double upgrade at Baird to Outperform with a sharply higher price target.
  • The move sharply diverged from peers, with several rival insurers trading lower on the same ratings release.

Opening Summary

HUM, the stock of Humana Inc., one of the largest U.S. health insurers focused on Medicare Advantage plans, staged a powerful rally on Thursday. Shares jumped approximately 14.47%, trading near $443.14 versus a prior session close of $387.12. The advance was driven almost entirely by the overnight release of CMS's 2027 Medicare Advantage Star Ratings, which showed a dramatic recovery in Humana's quality scores and restored its access to lucrative government bonus payments.

CMS Star Ratings Upgrade Fuels the Rally

The decisive driver behind the move was the annual Star Ratings release from the Centers for Medicare & Medicaid Services. Humana's flagship Medicare Advantage contract, covering roughly 2.4 million members, was upgraded to a four-star rating from 3.5 stars. That single step is consequential: plans rated four stars or higher become eligible for quality bonus payments, which flow directly into revenue and margins.

The turnaround was especially meaningful because Humana's ratings had deteriorated sharply in recent years. The share of members in four-star-or-better plans had fallen from about 94% to roughly 20%, costing the company billions in lost bonus revenue. The new ratings mark a reversal of that trend, with Humana reporting that about 95% of its members are now in plans rated four stars or higher. Analysts noted the improvement translated to a materially brighter earnings trajectory for 2028 and beyond.

Analyst Upgrades and Price-Target Hikes

The ratings surprise quickly rippled through the sell side. Baird upgraded HUM to Outperform from Neutral and lifted its price target to $596 from $390, citing the improved Star performance and confidence in the company's earnings power. Oppenheimer also raised its target to $475 from $405, calling Humana the "biggest winner" from the new ratings and estimating the improvement could represent billions of dollars in additional revenue. These upgrades reinforced investor conviction and helped sustain the stock's intraday strength.

Market Context and Trading Activity

The move in HUM was notable for its divergence from the broader managed-care group. While Humana surged, several competitors fell on the same CMS release, with UNH, ELV, CVS, and CNC all trading lower as their own Star Ratings showed relative weakness. CLOV, however, rose as a five-star beneficiary. The gap-up in Humana shares also cleared recent technical resistance, and trading volume was running well above typical levels as investors reacted to the announcement.

What Comes Next for HUM

Looking ahead, investors will monitor how quickly Humana can translate its restored Star Ratings into sustained earnings recovery. The financial benefit of the bonus payments largely materializes in 2028, meaning near-term focus remains on the company's margin execution and membership trends. The Medicare Advantage annual enrollment period opens in mid-October, providing an early read on 2027 membership. Regulatory and legal uncertainty also remains, including litigation around the CMS rating methodology and potential future changes to Medicare reimbursement, both of which could introduce volatility.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are currently among the strongest performers under live market conditions. Tickeron offers hundreds of bots spanning thousands of tickers, with each bot differentiated by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in the Trending AI Robots section. Explore the page to see which automated strategies are adapting best to today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HUM's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for HUM moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 47 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

HUM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 224 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

HUM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company offers health insurance coverage and related services

Industry ManagedHealthCare

Industry
Managed Health Care
Address
101 East Main Street
Phone
+1 502 580-1000
Employees
67060
Web
https://www.humana.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.